<DOC>
	<DOCNO>NCT00051454</DOCNO>
	<brief_summary>This study examine safety immune response two-part HIV vaccine . Healthy volunteer low risk HIV infection receive either active vaccine placebo .</brief_summary>
	<brief_title>Evaluation Safety Immune Response HIV Vaccine Healthy Adults</brief_title>
	<detailed_description>The purpose study examine safety immunogenicity candidate vaccine strategy HIV prophylaxis use DNA-prime plus recombinant fowlpox boost . The DNA plasmid fowlpox vector contain HIV gene . However , vaccine contain HIV gene cause HIV AIDS . Eligible volunteer low risk HIV infection randomize receive either active vaccine placebo injection Day 0 , Week 4 , Week 8 . Intensive immunologic safety monitor do first 16 week study . Follow-up continue Week 52 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria HIV negative . Acceptable method contraception . Exclusion Criteria Identifiable risk behavior HIV infection , include : sexual partner HIV positive people , sexual intercourse partner unknown HIV status partner report high risk HIV infection , gay men report unprotected anal intercourse partner unknown status 12 month precede study entry , individual diagnose sexually transmissible infection ( STI ) 12 month precede entry may acquire anal vaginal intercourse , individual report share inject equipment last 12 month . HIV candidate vaccine previous HIV vaccine trial . Live attenuate vaccine within 60 day prior enter study . Whole kill , toxoid , subunit vaccine ( e.g. , influenza , pneumococcal , tetanus , hepatitis B ) exclusionary within 4 week prior schedule experimental HIV vaccine . Hypersensitivity egg product know history anaphylaxis serious adverse reaction vaccination . History serious allergic reaction require hospitalization emergency medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) substance . Significant illness require immunomodulatory cytotoxic therapy . History cancer unless evidence surgical excision follow sufficient observation period give reasonable assurance cure . Blood product immunoglobulins within 6 month prior enter study . Experimental investigational agent within 30 day prior enter study . Recreational and/or therapeutic drug use might compromise study participant 's safety . Medical psychiatric condition occupational responsibility preclude compliance protocol . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>